Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních věcí,

kterým xx xxxx x xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo zahraničních xxxx xxxxxxx, xx xxx 1. xxxxx 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx zakázaných látek x xxxxx dopingu xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Přílohy X Českou xxxxxxxxxx.

Xxxx xxxxx Přílohy X xxxxxxxxx x platnost x souladu s článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx rok 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx pro Českou xxxxxxxxx xxx 22. xxxxxx 2023 a xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Přílohy X pro xxx 2024 x její xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. JUDr. Xxxxxx, Xx.X., XX.X., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx xxxxxxxx x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx je každoročně xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx zprostředkovaném Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx bude xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx. X případě jakýchkoliv xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.

Xxxx jsou xxxxxxx xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Při soutěži

Pokud XXXX xxx xxxx xxxxx neschválila xxxx xxxxxx, je období Xxx soutěži v xxxxxx obdobím xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x den předcházející Xxxxxxx, které xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, že daná xxxxx nebo metoda xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, jak xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Světového antidopingového Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx metodou, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx xxxx nebezpečné xxx xxxx dopingové xxxxx nebo metody. Xxx xxxxx x xxxxx x metody, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx nebo použil x xxxxxx xxxxx xxx xx zlepšení xxxxxxxxxxx xxxxxx.“

Xxxxxxxx látky

Podle xxxxxx 4.2.3 Kodexu xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou jako xxxxxx označeny x xxxxxx xxxxxx častého xxxxxxxxxx xx xxxxxxxxxxx xxxx rámec sportu. Xxxx Návykové látky xxxx označovány xxxx xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Specifické xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx xxxx v xxxxxxxx xxxx schválena xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (xxxx. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx zakázána stále.

Tato xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-dinitrofenol (XXX) a xxxxxxxxxx xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx zakázány.

S1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx včetně:

•	1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- ol)		•	quinbolon
•	dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, S-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující xxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (CERA)]; XXX- xxxxxxxxx prostředky a xxxxxx xxxxxxxxxx, např. XXXX-530, peginesatid.

S2.1.2 Aktivační xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (XXX 85-3934); xxxxxxxxxx (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx receptoru, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (CG),

• luteinizační xxxxxx (LH),

• hormon xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx analogy (např. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx hormon (XX), xxxx xxxxxxx x fragmenty, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x hGH 176–191.

X2.2.4 Xxxxxxx uvolňující růstový xxxxxx, mimo xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx xxxxxxx, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x xxxxxxxxxxx,

• xxxxxxxxxxx růstového hormonu (XXX) a xxxxxx xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, lenomorelin (xxxxxxx), xxxxxxxxxxx x tabimorelin],

• xxxxxxx uvolňující XX (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x jeho deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx všech xxxxxxxxx izomerů jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx dávce;

• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;

• inhalační xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx;

• xxxxxxxxx vilanterol: maximálně 25 mikrogramů za 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx xxx 1000 ng/ml nebo xxxxxxxxxxx x množství xxxxxx než 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx za Xxxxxxxxx laboratorní nález (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx do xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové a xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (arimistan)
•	3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, např.:
•	konkurenty receptoru xxxxxxxx IIB, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx expresi xxxxxxxxxx
	- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031)			- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx receptoru xxxxxxxx XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx peroxizomovými xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (GW1516, GW501516) x xxxxxxxx Xxx-xxxɑ , xxxx. SR9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx insulinů

S4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX LÁTKY

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx v této xxxxx xxxx Specifické xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx látky, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;

• Desmopresin;

• Xxxxxxxxxx;

x xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x lokální oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxx xx Vzorku Sportovce xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx s diuretikem xxxx jinou xxxxxxxxx xxxxxx (kromě lokálního xxxxxx podání inhibitoru xxxxxxxxxxxxxx nebo lokálního xxxxxx felypresinu x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Terapeutickou výjimku (XX) xx tuto xxxxx navíc x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX S XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx produktů z xxxxxxxxx krvinek jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a modifikované xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. CHEMICKÁ A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x xxxxxx xx xxxxxx porušit xxxxxxxxx a platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx infuze a/nebo xxxxxxx xxxx než xxxxxx 100 ml xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X BUNĚČNÝ DOPING

Z xxxxxx potencionálního zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

X3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.

X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x výjimkou xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx sekci: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- a x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-fenylpiracetam (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx xxxxxxx, např. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx imidazolinu v xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x stimulancia zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxx látky.

Návykové xxxxx v xxxx xxxxx: diamorfin (heroin)

Následující xxxxxxxxx, včetně jejich xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.

• x konopí (hašiš, xxxxxxxxx) x konopných xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (XXX)

• xxxxxxxxxx xxxxxxxxxxx napodobující xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI SOUTĚŽI

Všechny xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx acetonid
•	kortizon		•	hydrokortizon
•	deflazakort		•	metylprednisolon

POZNÁMKA

• Xxxx xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx se používají x rámci xxxxxxxx xxxxxxxxxxxx dávek a xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx a kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky na xxxxxx, xxxxxxxxxxx skoky / U-rampa a xxxxxxxxx X-xxxxx / xxx xxx

• xxxxxxxxxxxx xxxxx (XXX)

• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx potápění, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• xxxxx (XXX)

• xxxx (IGF)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx také Xxxx xxxxxx

Xxxx jiné xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x xxxx xxxxx xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx koncentraci v xxxx xxxxx než 150 xxxxxxxxxx x 1 ml.

³⁾ xxxxxxx x metylefedrin: xxxxxxxx xxx xxxxxxxxxxx x xxxx vyšší než 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): není xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx do Xxxxxxxxxxxxxx programu 2024 x xxxxxx považovány xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx dnem 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x odkazech není xxxxxxxxxxxxx, pokud xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx